In an excellent article, written jointly by Margaret Fisk, Jef Feeley, and David Voreacos for Bloomberg, some disturbing revelations involving Johnson & Johnson, a major drug manufacturer, were revealed. It was written that J&J made plans to reach $302 million in geriatric sales for its antipsychotic Risperdal just months after the FDA said the company falsely claimed the drug was safe and effective with the elderly. The FDA told J&J in 1999 that its marketing materials for geriatric patients overstated Risperdal’s benefits and minimized risks. But, even with that warning, a J&J business plan for 2000 called for increasing the drug’s market share for elderly dementia sales, an unapproved use. J&J officials even wrote in their business plan that “the geriatric market represents Risperdal’s second wave of growth.”
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.